| |
Transdermal Sustained Oxygen Therapy
EpiFLO® Product Benefits and User Advantages
- Easy to Use- no special storage conditions simple on/off switch attached to patient in 1-2 minutes.
- Minimal Training – Simply place oxygen cannula at center of wound and all other dressing go on top sequentially
- Fits all anatomic wound sites - The unit itself fits into a pocket so EpiFLO® can be used wherever a dressing can be placed
- Patient Mobility – the patient is free to ambulate and carry on with normal daily living while receiving treatment –EpiFLO® can be worn beneath clothing without impairing its operation
- Safe – non-implantable non ingestible, without tanks, chambers or oxygen storage , the low volume of oxygen is produced by the fuel cell and delivered to the wound in real time –no oxygen is stored
- Continuous Treatment for extended durations-uninterrupted Sustained Delivery of oxygen 24 hours a day for 15 or 7 days.
- Convenient – no daily trips to the hospital to receive oxygen treatment- dressing changes as needed to maintain good wound care.
|
- Cost effective – can reduce wound dressing needs & cost- Convincing economic advantages for health care
- Versatile- Compatible with outpatient, inpatient and community care environments
- Effective – May be used for a broad list of chronic wounds – Efficacy proven on most recalcitrant, non healing, or slow healing chronic wounds
- Compact – Dimensions 4.8cm X 6.0cm X 2.5 cm (approx.)
|
|
| |
|
How does it work?
EpiFLO® combines a specialized electrochemical process (state-of-the-art ‘fuel cell’ technology), in conjunction with a membrane, to concentrate the oxygen to near 100% for continuous 24/7 delivery via a small cannula directly to ‘blanket’ the wound with oxygen. The oxygen produced continuously flows into the 152 cm (60”) long #5 Fr. cannula.
The end of the cannula is placed onto the wound site and covered with an occlusive dressing or pressure dressing (see Instructions for Use). The dressing does not inflate and the patient has no sense of air movement. EpiFLO® provides silent, continuous, slow flow of oxygen (3 mL/h for either 7 or 15 days depending upon the type of EpiFLO® system used).
The oxygen delivered is at a low flow rate so the wound will not dry out. Some clinicians suggest that EpiFLO® mimics the bloodstream in delivering the necessary metabolic energy to oxygen starved cells. EpiFLO® energizes ischemic cells to ‘jump start’ the natural healing process.
Oxygen blanketing the wound helps metabolically to encourage cells to form extracellular matrix components including collagen and brings about tissue regeneration evidenced by new granulation tissue, neo-vascularization and other facets of skin development.
 Products
|
|
Comparison of Oxygen Treatment Modalities
EpiFLO® Differentiating Advantage
“…although treatment conditions were normobaric by design, partial oxygen tension in the exposed tissues approached similar levels to tension measured in hyperbaric oxygen therapy, delivered systemically by means of blood flow.”
Said, H.K. et al. Arch Surg. 2005; 140:998-1004 [Wound Healing Research Lab, Division of Plastic Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Ill.]s
| |
EpiFLO® |
HBO Chamber |
Topical Chamber |
| |
|
|
|
| |
|
|
|
| |
|
|
|
Method of action |
transdermal sustained delivery; continuous |
respiratory & systemic perfusion; intermittent |
topical perfusion; intermittent |
Daily oxygen exposure |
24 hrs continuous |
1.5 - 2.0 hrs |
1.5 - 2.0 hrs |
Hours of treatment per week |
168 hours |
6 - 10 hours |
6 - 10 hours |
Oxygen flow rate |
3 milliliters per hr |
600 liters per hr |
60 liters per hr |
Oxygen purity |
99+ % - maintains moist wound healing |
99+ % dry |
99+ % dry |
Oxygen pressure |
normobaric; 1.0 atm |
2.0 - 3.0 atm |
1.05 atm |
Local pO2 at wound site - during treatment |
350 - 400 mm Hg 24 / 7
(168 hours/week) |
1520 - 2280 mm Hg
(6 - 10 hours/week) |
798 mm Hg
(6 - 10 hours/week) |
Local pO2 at wound site under occlusive dressing - post treatment |
350 - 400 mm Hg continuous |
< 50 mm Hg |
< 50 mm Hg |
Dressing changes |
every 2 - 7 days; PRN |
after each treatment |
after each treatment |
Treatment target area |
wound under occlusive dressing |
full body |
entire limb |
Oxygen treatment risks |
none observed |
systemic nerve damage, death |
temporary tissue toxicity |
Treatment setting |
anywhere |
facility |
facility or home care |
Patient mobility during treatment |
fully ambulatory |
confined to chamber |
stationary |
System weight |
three ounces |
1,000’s - 10,000’s lbs |
varies, > 10 lbs |
|
| |
|
| |
|
